AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.-Reference-Cited by-同舟云学术

AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:8000-8000
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Ramalingam Suresh S.¹,Yang James Chih-Hsin²,Lee Chee Khoon³,Kurata Takayasu⁴,Kim Dong-Wan⁵,John Thomas⁶,Nogami Naoyuki⁷,Ohe Yuichiro⁸,Rukazenkov Yuri⁹,Frewer Paul⁹,Cantarini Mireille⁹,Ghiorghiu Serban¹⁰,Janne Pasi A.¹¹

Affiliation:

1. The Winship Cancer Institute of Emory University, Atlanta, GA

2. Department of Oncology, National Taiwan University Hospital; Graduate Institute of Oncology & Cancer Research Center, National Taiwan University, Taipei, Taiwan

3. St George Hospital, Sydney, Australia

4. Kansai Medical University Hirakata Hospital, Osaka-shi, Japan

5. Seoul National University Hospital, Seoul, South Korea

6. Olivia Newton-John Cancer Research Institute, Heidelberg, Australia

7. Clinical Research Institute, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

8. National Cancer Center Hospital East, Kashiwa, Japan

9. AstraZeneca, Macclesfield, United Kingdom

10. AstraZeneca, Cambridge, United Kingdom

11. Dana-Farber Cancer Institute, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject